The European Headache Federation (EHF) recently sought to create an expert- and evidence-based guideline for the treatment of migraine with monoclonal antibodies that target the calcitonin gene-related peptide (CGRP). However, in reviewing available research, the EHF found that there was not enough evidence to provide a guideline based on the Grading of Recommendation, Assessment, Development, and Evaluation approach.